These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 19692239)

  • 1. Improving potency and selectivity of a new class of non-Zn-chelating MMP-13 inhibitors.
    Heim-Riether A; Taylor SJ; Liang S; Gao DA; Xiong Z; Michael August E; Collins BK; Farmer BT; Haverty K; Hill-Drzewi M; Junker HD; Mariana Margarit S; Moss N; Neumann T; Proudfoot JR; Keenan LS; Sekul R; Zhang Q; Li J; Farrow NA
    Bioorg Med Chem Lett; 2009 Sep; 19(18):5321-4. PubMed ID: 19692239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SAR studies of non-zinc-chelating MMP-13 inhibitors: improving selectivity and metabolic stability.
    Gao DA; Xiong Z; Heim-Riether A; Amodeo L; August EM; Cao X; Ciccarelli L; Collins BK; Harrington K; Haverty K; Hill-Drzewi M; Li X; Liang S; Margarit SM; Moss N; Nagaraja N; Proudfoot J; Roman R; Schlyer S; Keenan LS; Taylor S; Wellenzohn B; Wiedenmayer D; Li J; Farrow NA
    Bioorg Med Chem Lett; 2010 Sep; 20(17):5039-43. PubMed ID: 20675133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extra binding region induced by non-zinc chelating inhibitors into the S1' subsite of matrix metalloproteinase 8 (MMP-8).
    Pochetti G; Montanari R; Gege C; Chevrier C; Taveras AG; Mazza F
    J Med Chem; 2009 Feb; 52(4):1040-9. PubMed ID: 19173605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-resolution solution structure of the catalytic fragment of human collagenase-3 (MMP-13) complexed with a hydroxamic acid inhibitor.
    Moy FJ; Chanda PK; Chen JM; Cosmi S; Edris W; Levin JI; Powers R
    J Mol Biol; 2000 Sep; 302(3):671-89. PubMed ID: 10986126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3,4-Disubstituted benzofuran P1' MMP-13 inhibitors: optimization of selectivity and reduction of protein binding.
    Li W; Hu Y; Li J; Thomason JR; DeVincentis D; Du X; Wu J; Hotchandani R; Rush TS; Skotnicki JS; Tam S; Chockalingam PS; Morris EA; Levin JI
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4546-50. PubMed ID: 19625186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural basis for the highly selective inhibition of MMP-13.
    Engel CK; Pirard B; Schimanski S; Kirsch R; Habermann J; Klingler O; Schlotte V; Weithmann KU; Wendt KU
    Chem Biol; 2005 Feb; 12(2):181-9. PubMed ID: 15734645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors.
    Kiyama R; Tamura Y; Watanabe F; Tsuzuki H; Ohtani M; Yodo M
    J Med Chem; 1999 May; 42(10):1723-38. PubMed ID: 10346925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. X-ray structure of human stromelysin catalytic domain complexed with nonpeptide inhibitors: implications for inhibitor selectivity.
    Pavlovsky AG; Williams MG; Ye QZ; Ortwine DF; Purchase CF; White AD; Dhanaraj V; Roth BD; Johnson LL; Hupe D; Humblet C; Blundell TL
    Protein Sci; 1999 Jul; 8(7):1455-62. PubMed ID: 10422833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective non zinc binding inhibitors of MMP13.
    De Savi C; Morley AD; Ting A; Nash I; Karabelas K; Wood CM; James M; Norris SJ; Karoutchi G; Rankine N; Hamlin G; Macfaul PA; Ryan D; Baker SV; Hargreaves D; Gerhardt S
    Bioorg Med Chem Lett; 2011 Jul; 21(14):4215-9. PubMed ID: 21669521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of potent and selective MMP-13 inhibitors.
    Wu J; Rush TS; Hotchandani R; Du X; Geck M; Collins E; Xu ZB; Skotnicki J; Levin JI; Lovering FE
    Bioorg Med Chem Lett; 2005 Sep; 15(18):4105-9. PubMed ID: 16005220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.
    Schnute ME; O'Brien PM; Nahra J; Morris M; Howard Roark W; Hanau CE; Ruminski PG; Scholten JA; Fletcher TR; Hamper BC; Carroll JN; Patt WC; Shieh HS; Collins B; Pavlovsky AG; Palmquist KE; Aston KW; Hitchcock J; Rogers MD; McDonald J; Johnson AR; Munie GE; Wittwer AJ; Man CF; Settle SL; Nemirovskiy O; Vickery LE; Agawal A; Dyer RD; Sunyer T
    Bioorg Med Chem Lett; 2010 Jan; 20(2):576-80. PubMed ID: 20005097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based design and synthesis of novel non-zinc chelating MMP-12 inhibitors.
    Dublanchet AC; Ducrot P; Andrianjara C; O'Gara M; Morales R; Compère D; Denis A; Blais S; Cluzeau P; Courté K; Hamon J; Moreau F; Prunet ML; Tertre A
    Bioorg Med Chem Lett; 2005 Aug; 15(16):3787-90. PubMed ID: 16002291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of novel molecular scaffolds for the design of MMP-13 inhibitors: a first round of lead optimization.
    La Pietra V; Marinelli L; Cosconati S; Di Leva FS; Nuti E; Santamaria S; Pugliesi I; Morelli M; Casalini F; Rossello A; La Motta C; Taliani S; Visse R; Nagase H; da Settimo F; Novellino E
    Eur J Med Chem; 2012 Jan; 47(1):143-52. PubMed ID: 22088955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent and selective 2-naphthylsulfonamide substituted hydroxamic acid inhibitors of matrix metalloproteinase-13.
    Tommasi RA; Weiler S; McQuire LW; Rogel O; Chambers M; Clark K; Doughty J; Fang J; Ganu V; Grob J; Goldberg R; Goldstein R; Lavoie S; Kulathila R; Macchia W; Melton R; Springer C; Walker M; Zhang J; Zhu L; Shultz M
    Bioorg Med Chem Lett; 2011 Nov; 21(21):6440-5. PubMed ID: 21937229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent, selective spiropyrrolidine pyrimidinetrione inhibitors of MMP-13.
    Freeman-Cook KD; Reiter LA; Noe MC; Antipas AS; Danley DE; Datta K; Downs JT; Eisenbeis S; Eskra JD; Garmene DJ; Greer EM; Griffiths RJ; Guzman R; Hardink JR; Janat F; Jones CS; Martinelli GJ; Mitchell PG; Laird ER; Liras JL; Lopresti-Morrow LL; Pandit J; Reilly UD; Robertson D; Vaughn-Bowser ML; Wolf-Gouviea LA; Yocum SA
    Bioorg Med Chem Lett; 2007 Dec; 17(23):6529-34. PubMed ID: 17935984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent, selective pyrone-based inhibitors of stromelysin-1.
    Puerta DT; Mongan J; Tran BL; McCammon JA; Cohen SM
    J Am Chem Soc; 2005 Oct; 127(41):14148-9. PubMed ID: 16218585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pyrimidine-2,4,6-Triones: a new effective and selective class of matrix metalloproteinase inhibitors.
    Grams F; Brandstetter H; D'Alò S; Geppert D; Krell HW; Leinert H; Livi V; Menta E; Oliva A; Zimmermann G; Gram F; Brandstetter H; D'Alò S; Geppert D; Krell HW; Leinert H; Livi VMenta E; Oliva A; Zimmermann G
    Biol Chem; 2001 Aug; 382(8):1277-85. PubMed ID: 11592410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the subtleties of drug-receptor interactions: the case of matrix metalloproteinases.
    Bertini I; Calderone V; Fragai M; Giachetti A; Loconte M; Luchinat C; Maletta M; Nativi C; Yeo KJ
    J Am Chem Soc; 2007 Mar; 129(9):2466-75. PubMed ID: 17269766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benzisothiazolyliminothiazolidin-4-ones with chondroprotective properties: searching for potent and selective inhibitors of MMP-13.
    Vicini P; Crascì L; Incerti M; Ronsisvalle S; Cardile V; Panico AM
    ChemMedChem; 2011 Jul; 6(7):1199-202. PubMed ID: 21661113
    [No Abstract]   [Full Text] [Related]  

  • 20. Crystal structures of novel non-peptidic, non-zinc chelating inhibitors bound to MMP-12.
    Morales R; Perrier S; Florent JM; Beltra J; Dufour S; De Mendez I; Manceau P; Tertre A; Moreau F; Compere D; Dublanchet AC; O'Gara M
    J Mol Biol; 2004 Aug; 341(4):1063-76. PubMed ID: 15289103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.